Banzel Oral Suspension Approved as Adjunct Therapy for Seizures

The FDA has approved Banzel (rufinamide; Eisai) oral suspension for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥4 years old. The oral suspension formulation is bioequivalent to the already available Banzel tablet formulation on a milligram per milligram basis.

Banzel oral suspension will be available late March in a 40mg/mL concentration.

For more information call (888) 422-4743 or visit